Skip to main content
SpringerLink
Log in

Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer

  • Clinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Fifty patients with histologically confirmed advanced malignancies were treated with ifosfamide and mesna plus other cytostatics. The other cytostatic drugs added to the treatment regimen were cisplatin (36 pts), etoposide (31 pts) and doxorubicin (20 pts). Among previously untreated patients objective response was documented in 12 of 19 pts with ovarian cancer, 9 of 14 with small cell cancer of the lung and in all 3 pts with Ewing's sarcoma. Among patients with disease refractory to prior cytostatic treatment, objective response was documented in 8 of 9 with testicular cancer, 1 of 3 with high grade lymphoma and 0 of 2 with osteosarcoma. Side-effects due to the combination of ifosfamide plus mesna and other cytostatics were acceptable. No life-threatening or lethal toxicities occurred. Most commonly encountered toxicities were leukopenia (64%), nausea and vomiting (84%), alopecia (63%), CNS toxicity (30%) and renal toxicity (12%).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brock N: The special position of ifosfamide in the series of cytostatically active oxazaphosphorines. In: Fox BW (ed) Advances in Medical Oncology. Research and Education. Pergamon Press, Oxford and New York, 1979, pp 39–47

    Google Scholar 

  2. Van Dyk JJ, Falkson HC, Van der Merwe AM, Falkson G: Unexpected toxicity in patients treated with iphosphamide. Cancer Res 32: 921–924, 1972

    Google Scholar 

  3. Falkson G, Van Dyk JJ, Stapelberg R, Falkson HC: Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment. Cancer Chemother Pharmaco19: 81–84, 1982

    Google Scholar 

  4. Falkson CI, Falkson HC, Falkson G: Ifosfamide and Mesna in the treatment of malignant disease. Mesna as urothelial protector. In press: Invest New Drugs, 1989

  5. Goldin A: Ifosfamide in experimental tumor systems. Semin Oncol 9: 14–23, 1982

    Google Scholar 

  6. Goldin A: Dosing and sequencing for antineoplastic synergism. Cancer 54: 155–1160, 1984

    Google Scholar 

  7. Fichtner I, Nowak CH: Pharmacological and toxicological effects of ifosfamide (holoxan) combined with mesna (uromitexan) in different murine tumor models. In: Brade, Nagel, Seeber (eds) Contr Oncol Basel, Karger 1987, 26: pp 93–104

  8. Hartlapp JH, Illiger HJ, Wolter H: Alternatives to CYVADIC combination therapy of soft-tissue sarcoma. Klin Wochenschr 63: 1160–1162, 1985

    Google Scholar 

  9. Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, Wesley R, Magrath I: Ifosfamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5: 1191–1198, 1987

    Google Scholar 

  10. Einhorn LH: Ifosfamide in small cell lung cancer. Semin Oncol 16: 19–21 1989

    Google Scholar 

  11. Cantwell HMJ, Carmichael J, Ghani S, Harris AL: A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma. Cancer Chemother Pharmacol 1: 49–52, 1988

    Google Scholar 

  12. Wiltshaw E, Westburg G, Harmer C, McKinna A, Fisher C: Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. Cancer Chemother Pharmacol 18: S10-S12, 1986

    Google Scholar 

  13. Oken MM, Creech RH, Tormey D, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655, 1982

    CAS  PubMed  Google Scholar 

  14. Zalupski M, Baker LH: Ifosfamide. J Natl Cancer Inst 80: 556–566, 1988

    Google Scholar 

  15. Falkson G, Falkson HC: Further experience with Isophosphamide. Cancer Treat Rep 60: 955–957, 1976

    Google Scholar 

  16. Yazigi R, Wild R, Madrid J, Arraztoa J: Ifosfamide treatment of advanced ovarian cancer. Obstet Gynecol 63: 163–166, 1984

    Google Scholar 

  17. Slater AJ, Green JA: Phase II Study of Cisplatin and Ifosfamide in the Treatment of Advanced Ovarian Carcinoma presented at the 13th International Cancer Congress, Seattle, 1982

  18. Wheeler BM, Loehrer PJ, Williams SD, Einhorn LH: Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4: 28–34, 1986

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University of Pretoria, Pretoria, South Africa

    Geoffrey Falkson, Martin R. Chasen & Hendrè C. Falkson

Authors
  1. Geoffrey Falkson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin R. Chasen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hendrè C. Falkson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Falkson, G., Chasen, M.R. & Falkson, H.C. Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer. Invest New Drugs 8, 215–219 (1990). https://doi.org/10.1007/BF00177264

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00177264

Key words

Search

Navigation